Science Explorer Back to mapMap

Most cited papers from Merrimack Pharmaceuticals (United States)

What are the most cited papers from Merrimack Pharmaceuticals (United States)?

The most cited paper from Merrimack Pharmaceuticals (United States) is "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial" (Andrea Wang‐Gillam et al., 2015), with 1,232 citations. Next come "Systems biology and combination therapy in the quest for clinical efficacy" (591) and "Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics" (478).

Showing 50 of 60 papers. Every paper with more than 61 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Andrea Wang‐Gillam et al. · The Lancet 29 Nov 2015 1,232
2 Systems biology and combination therapy in the quest for clinical efficacy Jonathan B. Fitzgerald, Birgit Schoeberl, Ulrik B. Nielsen et al. · Nature Chemical Biology 18 Aug 2006 591
3 Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics Manu P. Kumar, Jinyan Du, Georgia Lagoudas et al. · Cell Reports Open access Nov 2018 478
4 Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data William W. Chen, Birgit Schoeberl, Paul Jasper et al. · Molecular Systems Biology Open access 20 Jan 2009 407
5 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer Helen Lee, Anthony Frank Shields, Barry Alan Siegel et al. · Clinical Cancer Research Open access 15 Mar 2017 386
6 Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis Birgit Schoeberl, Emily A. Pace, Jonathan B. Fitzgerald et al. · Science Signaling 30 Jun 2009 369
7 Lessons Learned from Quantitative Dynamical Modeling in Systems Biology Andreas Raue, Marcel Schilling, Julie Bachmann et al. · PLoS ONE Open access 30 Sep 2013 364
8 Estimation of immune cell content in tumour tissue using single-cell RNA-seq data Max Schelker, Sonia Feau, Jinyan Du et al. · Nature Communications Open access 5 Dec 2017 348
9 Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 Charlotte Fenton McDonagh, Alexandra Huhalov, Brian D. Harms et al. · Molecular Cancer Therapeutics 16 Jan 2012 277
10 Data2Dynamics: a modeling environment tailored to parameter estimation in dynamical systems Andreas Raue, Bernhard Steiert, Max Schelker et al. · Bioinformatics Open access 3 Jul 2015 270
11 An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation Birgit Schoeberl, Anthony C. Faber, Danan Li et al. · Cancer Research Open access 9 Mar 2010 261
12 Effects of HER2 overexpression on cell signaling networks governing proliferation and migration Alejandro Wolf‐Yadlin, Neil Kumar, Yi Zhang et al. · Molecular Systems Biology Open access 3 Oct 2006 256
13 Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism Douglas J. Marcotte et al. · Bioorganic & Medicinal Chemistry Open access 19 Apr 2013 243
14 An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells Qing Sheng, Xinggang Liu, ELEANOR M. FLEMING et al. · Cancer Cell Open access Mar 2010 238
15 Profiling receptor tyrosine kinase activation by using Ab microarrays Ulrik B. Nielsen, Mike H. Cardone, Anthony J. Sinskey et al. · Proceedings of the National Academy of Sciences Open access 22 Jul 2003 227
16 The Response of Human Epithelial Cells to TNF Involves an Inducible Autocrine Cascade Kevin A. Janes, Suzanne Gaudet, John G. Albeck et al. · Cell Open access Mar 2006 222
17 Viral contamination in biologic manufacture and implications for emerging therapies Paul W. Barone et al. · Nature Biotechnology Open access 27 Apr 2020 215
18 Control of MAPK signalling: from complexity to what really matters Jorrit J. Hornberg, Bernd R. Binder, Frank J. Bruggeman et al. · Oncogene 20 Jun 2005 204
19 Multiplexed sandwich assays in microarray format Ulrik B. Nielsen, Bernhard H. Geierstanger · Journal of Immunological Methods 31 May 2004 200
20 Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion Ashish V. Kalra, Jaeyeon Kim, Stephan G. Klinz et al. · Cancer Research 2 Oct 2014 198
21 Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Ramesh K. Ramanathan, Ronald Lee Korn, Natarajan Raghunand et al. · Clinical Cancer Research 3 Feb 2017 178
22 Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma Antoni Ribas, Theresa Medina, John M. Kirkwood et al. · Cancer Discovery Open access 29 Jul 2021 175
23 HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer Kathy D. Miller, Javier Cortés, Sara A. Hurvitz et al. · BMC Cancer Open access 3 Jun 2016 167
24 A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines Suzanne Gaudet, Kevin A. Janes, John G. Albeck et al. · Molecular & Cellular Proteomics Open access 19 Jul 2005 162
25 Fractional killing arises from cell‐to‐cell variability in overcoming a caspase activity threshold Jérémie Roux, Marc A. Hafner, Samuel Bandara et al. · Molecular Systems Biology Open access May 2015 151
26 Effects of Bcl-2 Levels on Fas Signaling-Induced Caspase-3 Activation: Molecular Genetic Tests of Computational Model Predictions Fei Hua, Melanie Cornejo, Michael H. Cardone et al. · The Journal of Immunology Open access Jul 2005 140
27 Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study Pamela N. Münster, Ian E. Krop, Patricia Mucci LoRusso et al. · British Journal of Cancer Open access Oct 2018 134
28 Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer Christopher W. Espelin, Shannon Curtis Leonard, Elena Geretti et al. · Cancer Research 13 Jan 2016 134
29 Effects of insulin-like growth factor-1 and dexamethasone on cytokine-challenged cartilage: relevance to post-traumatic osteoarthritis Y. Li, Yan Wang, Susan Chubinskaya et al. · Osteoarthritis and Cartilage Open access 10 Nov 2014 126
30 HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity Joseph G. Reynolds, Elena Geretti, Bart S. Hendriks et al. · Toxicology and Applied Pharmacology 21 Apr 2012 123
31 Driving the Model to Its Limit: Profile Likelihood Based Model Reduction Tim Maiwald, Helge Hass, Bernhard Steiert et al. · PLoS ONE Open access 2 Sep 2016 111
32 Canine spontaneous glioma: A translational model system for convection-enhanced delivery Peter J. Dickinson, Richard A. LeCouteur, Robert Higgins et al. · Neuro-Oncology Open access 20 May 2010 110
33 Shear- and Compression-induced Chondrocyte Transcription Requires MAPK Activation in Cartilage Explants Jonathan B. Fitzgerald, Moonsoo M. Jin, Diana H. Chai et al. · Journal of Biological Chemistry Open access 18 Dec 2007 110
34 Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery Huang‐Chiao Huang, Imran Rizvi, Joyce Liu et al. · Cancer Research Open access 29 Nov 2017 108
35 Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors Daniel C. Kirouac, Jin Du, Johanna Lahdenranta et al. · Science Signaling 13 Aug 2013 107
36 Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients Matthew Onsum, Elena Geretti, Violette B. Paragas et al. · American Journal Of Pathology Open access 11 Sep 2013 107
37 MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum et al. · Molecular Cancer Therapeutics 27 Nov 2013 103
38 Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines Mario Niepel, Marc A. Hafner, Emily A. Pace et al. · Science Signaling Open access 24 Sep 2013 102
39 Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression Min H. Kang, Jing Wang, Monish Ram Makena et al. · Clinical Cancer Research Mar 2015 102
40 Competing Docking Interactions can Bring About Bistability in the MAPK Cascade Stefan Legewie, Birgit Schoeberl, Nils Blüthgen et al. · Biophysical Journal Open access 25 May 2007 96
41 The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy Jodi A. McKenzie et al. · JNCI Journal of the National Cancer Institute Open access 27 Nov 2017 93
42 MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations Sabrina Arena, Giulia Siravegna, Benedetta Mussolin et al. · Science Translational Medicine Open access 3 Feb 2016 93
43 Combining guilt-by-association and guilt-by-profiling to predict Saccharomyces cerevisiaegene function Weidong Tian, Lan V. Zhang, Murat Taşan et al. · Genome biology Open access 27 Jun 2008 93
44 A comparison of specific space diversity techniques for reduction of fast fading in UHF mobile radio systems William C. Jakes · IEEE Transactions on Vehicular Technology Nov 1971 92
45 Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials” Jon S. B. de Vlieger, Daan J.A. Crommelin, Katherine M. Tyner et al. · The AAPS Journal Open access 17 Apr 2019 91
46 Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts Pin Yuan Chen, Tomoko Ozawa, Daryl C. Drummond et al. · Neuro-Oncology Open access 21 Dec 2012 90
47 Birth-Death and Bug Counting W. Kremer · IEEE Transactions on Reliability Apr 1983 84
48 Network topology and parameter estimation: from experimental design methods to gene regulatory network kinetics using a community based approach Pablo Meyer, Thomas Cokelaer, Deepak Chandran et al. · BMC Systems Biology Open access 2014 80
49 A novel screening method to assess developability of antibody-like molecules Neeraj Kohli, Neha Jain, Melissa L. Geddie et al. · mAbs Open access 11 May 2015 77
50 Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121) Birgit Schoeberl et al. · npj Systems Biology and Applications Open access 5 Jan 2017 76

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.